Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Area of Science:

• Oncology
• Genetics
• Reproductive Biology

Background:

• Poly(ADP-ribose) polymerase (PARP) is crucial for DNA repair.
• PARP inhibitors (PARPi) are effective targeted cancer therapies, especially for BRCA mutations.
• PARPi use raises concerns about ovarian function, particularly in younger patients.

Purpose of the Study:

• To review the current knowledge on PARPi's impact on ovarian function.
• To explore the potential mechanisms behind PARPi-induced ovarian toxicity.
• To emphasize the need for criteria and prevention strategies for ovarian failure during PARPi treatment.

Main Methods:

• Literature review of existing studies on PARPi and ovarian function.
• Analysis of proposed molecular mechanisms of PARPi's effect on ovaries.
• Discussion of clinical implications and future research directions.

Main Results:

• PARPi can negatively affect ovarian function, leading to potential infertility.
• Mechanisms may involve direct toxicity to ovarian cells or disruption of DNA repair pathways.
• Limited data exists on specific criteria for ovarian failure and effective prevention.

Conclusions:

• PARPi's effects on ovarian function require careful consideration in cancer treatment.
• Understanding the underlying mechanisms is key to developing protective strategies.
• Further research is essential to establish guidelines for managing and preventing ovarian failure in patients receiving PARPi therapy.